Literature DB >> 30103144

Determination of the formation rate of phosphatidylethanol by phospholipase D (PLD) in blood and test of two selective PLD inhibitors.

Alexandra Schröck1, Anna Henzi2, Peter Bütikofer3, Stefan König2, Wolfgang Weinmann4.   

Abstract

Phosphatidylethanol (PEth) is an alcohol biomarker formed from phosphatidylcholine (PC) by the enzyme phospholipase D (PLD) in the presence of ethanol. A drinking study revealed individual differences in maximum PEth levels after drinking to a targeted blood alcohol concentration (BAC) of 0.1%. This seemed to be due to different PLD activities in the tested persons. Furthermore, post-sampling formation of PEth occurred in blood samples, still containing alcohol. Therefore, a standardized in vitro test for measuring individual PEth formation rates was developed. Two PLD inhibitors were tested for their potency to inhibit post-sampling PEth formation. PEth-negative blood samples were collected from a volunteer. Ethanol was added in different concentrations (0.01-0.3% BAC) directly after blood sampling. The specimens were incubated at 37 °C. Aliquots were taken at the start of the incubation, and every hour until 8 h after start of incubation, and one sample was taken on subsequent days over 1 week. PEth 16:0/18:1 and PEth 16:0/18:2 were determined by online SPE-LC-MS/MS. Furthermore, this test system was applied to blood samples of 12 volunteers. For the inhibition tests, fresh blood (spiked with 0.1% ethanol) was spiked with 30, 300, 3000, or 30,000 nM of either halopemide or 5-fluoro-2-indolyl-deschlorohalopemide (FIPI), and incubated at 37 °C. PEth concentrations were determined hourly over 5 h on the first day and once on day 2 and day 3. PEth formation was linear in the first 7 h of incubation and dependent on the alcohol concentration. The formation rates of PEth 16:0/18:1 were 0.002 μmol L-1 h-1 (0.01% BAC), 0.016 μmol L-1 h-1 (0.1% BAC), 0.025 μmol L-1 h-1 (0.2% BAC), and 0.029 μmol L-1 h-1 (0.3% BAC). For PEth 16:0/18:2, the formation rates were 0.002 μmol L-1 h-1 (0.01% BAC), 0.019 μmol L-1 h-1 (0.1% BAC), 0.025 μmol L-1 h-1 (0.2% BAC), and 0.030 μmol L-1 h-1 (0.3% BAC). Maximum concentrations reached 431 ng/mL (PEth 16:0/18:1) and 496 ng/mL (PEth 16:0/18:2) at 0.3% BAC after 3 days. Maximum velocity (vmax) was not reached under these conditions. PEth formation in blood of the 12 volunteers ranged between 0.011 and 0.025 μmol L-1 h-1 for PEth 16:0/18:1 and between 0.014 and 0.021 μmol L-1 h-1 for PEth 16:0/18:2. PEth formation in human blood was inhibited by halopemide in a concentration-dependent manner. However, a complete inhibition was not achieved by the applied maximum concentration of 30,000 nM. FIPI showed a better inhibition of PEth formation. A complete inhibition could be achieved by a concentration of 30,000 nM for the first 24 h (for PEth 16:0/18:1) and for 48 h (for PEth 16:0/18:2). Formation of PEth was found to be dependent on the BAC. As a consequence, it is essential to inhibit PLD activity after blood collection to avoid post-sampling formation of PEth in blood samples with a positive BAC. Inhibition of PEth formation was more effective using FIPI, compared to halopemide.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcohol biomarker; Online SPE-LC-MS/MS; PEth formation rate; PLD inhibitors; Phosphatidylethanol (PEth); Phospholipase D (PLD) activity

Mesh:

Substances:

Year:  2018        PMID: 30103144     DOI: 10.1016/j.alcohol.2018.03.003

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  5 in total

Review 1.  Evolution of the liver biopsy and its future.

Authors:  Dhanpat Jain; Richard Torres; Romulo Celli; Jeremy Koelmel; Georgia Charkoftaki; Vasilis Vasiliou
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

2.  Phosphatidylethanol, ethyl glucuronide and ethanol in blood as complementary biomarkers for alcohol consumption.

Authors:  Jasna Neumann; Olof Beck; Michael Böttcher
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-10-05

3.  Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: An individual patient data meta-analysis.

Authors:  Judith A Hahn; Pamela M Murnane; Eric Vittinghoff; Winnie R Muyindike; Nneka I Emenyonu; Robin Fatch; Gabriel Chamie; Jessica E Haberer; Joel M Francis; Saidi Kapiga; Karen Jacobson; Bronwyn Myers; Marie Claude Couture; Ralph J DiClemente; Jennifer L Brown; Kaku So-Armah; Mark Sulkowski; Gregory M Marcus; Sarah Woolf-King; Robert L Cook; Veronica L Richards; Patricia Molina; Tekeda Ferguson; David Welsh; Mariann R Piano; Shane A Phillips; Scott Stewart; Majid Afshar; Kimberly Page; Kathleen McGinnis; David A Fiellin; Amy C Justice; Kendall Bryant; Richard Saitz
Journal:  Alcohol Clin Exp Res       Date:  2021-05-07       Impact factor: 3.928

4.  Measurement of the alcohol biomarker phosphatidylethanol (PEth) in dried blood spots and venous blood-importance of inhibition of post-sampling formation from ethanol.

Authors:  Olof Beck; Maria Mellring; Christian Löwbeer; Sabina Seferaj; Anders Helander
Journal:  Anal Bioanal Chem       Date:  2021-02-15       Impact factor: 4.142

5.  The Association between the Alcohol Biomarker Phosphatidylethanol (PEth) and Self-Reported Alcohol Consumption among Russian and Norwegian Medical Patients.

Authors:  Benedicte Jørgenrud; Saranda Kabashi; Aleksei Nadezhdin; Evgeny Bryun; Evgenya Koshkina; Elena Tetenova; Anners Lerdal; Gudmund Norby; Alexey Kolgashkin; Alexei Petukhov; Sergey Perekhodov; Elena Davydova; Vigdis Vindenes; Danil Gamboa; Stig Tore Bogstrand
Journal:  Alcohol Alcohol       Date:  2021-10-29       Impact factor: 2.826

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.